Molecular Biology Reports

, Volume 41, Issue 2, pp 751–756 | Cite as

Toremifene and tamoxifen have similar efficacy in the treatment of patients with breast cancer: a meta-analysis of randomized trials

  • Qian-ling Ye
  • Zhi-min ZhaiEmail author


A meta-analysis of randomized trials was performed to compare the efficacy of toremifene (TOR) with tamoxifen (TAM) in patients with breast cancer. A total of 4,768 intention-to-treat patients from nine randomized trials were identified, with 2,587 patients in TOR group and 2,181 patients in TAM group. The primary outcomes were objective response rate (ORR), time to progression (TTP), and overall survival (OS). The ORR for TOR group was 26.2 % (303/1,156), whereas the ORR for TAM group was 25.2 % (284/1,128). The pooled RR suggested that the ORR were not statistically different between the two therapeutic groups (RR 1.04, 95 % CI 0.91–1.20, P = 0.57). The median TTP was 6.7 months for the TOR group and 9.7 months for the TAM group. The median OS was 30.1 months for the TOR group and 31.7 months for the TAM group. There were no significant difference in TTP and OS between two therapeutic groups (for TTP: HR 0.91, 95 % CI 0.82–1.00; for OS: HR 1.02, 95 % CI 0.91–1.15). Adverse events were generally similar in two therapeutic groups, but TOR may cause fewer vaginal bleeding (4.0 vs. 6.7 %, P < 0.01), headache (0.2 vs. 3.1 %, P = 0.02) and thromboembolic events (4.7 vs. 7.0 %, P = 0.04). Sensitivity analyses were performed by deleting a single study each time; all the results were not materially altered. In summary, the results of this meta-analysis suggest that TOR and TAM have similar efficacy in the treatment of patients with breast cancer.


Toremifene Tamoxifen Breast cancer Meta-analysis 



Complete response


Confidence interval


Estrogen receptor


Hazard ratio


Objective response rate


Overall survival


Partial response


Relative risk




Time to progression




  1. 1.
    Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1–15Google Scholar
  2. 2.
    Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN (1995) Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13:513–529PubMedGoogle Scholar
  3. 3.
    Clemons M, Danson S, Howell A (2002) Tamoxifen (‘Nolvadex’): a review. Cancer Treat Rev 28:165–180CrossRefPubMedGoogle Scholar
  4. 4.
    Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351:1451–1467CrossRefGoogle Scholar
  5. 5.
    Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRefGoogle Scholar
  6. 6.
    Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388CrossRefPubMedGoogle Scholar
  7. 7.
    Tamoxifen information: reducing the incidence of breast cancer in women at high risk. Accessed 3 July 2007
  8. 8.
    Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609–1618CrossRefPubMedGoogle Scholar
  9. 9.
    Kangas L, Kallio S, Blanco G, Grönroos M, Kallio S, Karjalainen A, Perilä M, Södervall M, Toivola R (1986) A new triphenylethylene compound, FC-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 17:109–113CrossRefPubMedGoogle Scholar
  10. 10.
    Kangas L (1992) Agonistic and antagonistic effects of antiestrogens in different target organs. Acta Oncol 31:143–146CrossRefPubMedGoogle Scholar
  11. 11.
    di Salle E, Zaccheo T, Ornati G (1990) Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 36:203–206CrossRefPubMedGoogle Scholar
  12. 12.
    Warri AM, Huovinen RL, Laine AM, Martikainen PM, Harkonen PL (1993) Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 85:1412–1418CrossRefPubMedGoogle Scholar
  13. 13.
    Hirsimaki PAA, Mantyla E (2002) Toxicity of antiestrogens. Breast J 8:92–96CrossRefPubMedGoogle Scholar
  14. 14.
    Nomura Y, Tominaga T, Abe O, Izuo M, Ogawa N (1993) Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer—a comparative study by a double blind method with tamoxifen. Gan To Kagaku Ryoho 20:247–258PubMedGoogle Scholar
  15. 15.
    Stenbygaard LE, Herrstedt J, Thomsen JF, Svendsen KR, Engelholm SA, Dombernowsky P (1993) Toremifene and tamoxifen in advanced breast cancer-a double-blind cross-over trial. Breast Cancer Res Treat 25:57–63CrossRefPubMedGoogle Scholar
  16. 16.
    Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, Schoenfelder J (1995) Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13:2556–2566PubMedGoogle Scholar
  17. 17.
    Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmén J (1997) A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res Treat 45:251–262CrossRefPubMedGoogle Scholar
  18. 18.
    Pyrhönen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, Bauer J, Westman G, Lundgren S, Blanco G, Mella O, Nilsson I, Hietanen T, Hindy I, Vuorinen J, Hajba A (1997) Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the ‘nordic’ phase III study. Br J Cancer 76:270–277CrossRefPubMedGoogle Scholar
  19. 19.
    Milla-Santos A, Milla L, Rallo L, Solano V (2001) Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res Treat 65:119–124CrossRefPubMedGoogle Scholar
  20. 20.
    International Breast Cancer Study Group, Pagani O, Gelber S, Price K, Zahrieh D, Gelber R, Simoncini E, Castiglione-Gertsch M, Coates AS, Goldhirsch A (2004) Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 15:1749–1759CrossRefGoogle Scholar
  21. 21.
    Gianni L, Gelber S, Ravaioli A, Price KN, Panzini I, Fantini M, Castiglione-Gertsch M, Pagani O, Simoncini E, Gelber RD, Coates AS, Goldhirsch A (2009) Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group. Eur J Cancer 45:561–571CrossRefPubMedGoogle Scholar
  22. 22.
    Lewis JD, Chagpar AB, Shaughnessy EA, Nurko J, McMasters K, Edwards MJ (2010) Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. Cancer 116:2307–2315CrossRefPubMedGoogle Scholar
  23. 23.
    Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129CrossRefGoogle Scholar
  24. 24.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214CrossRefPubMedGoogle Scholar
  25. 25.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMedGoogle Scholar
  26. 26.
    Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17Google Scholar
  27. 27.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Pyrhönen SO (1990) Phase III studies of toremifene in metastatic breast cancer. Breast Cancer Res Treat 16(Suppl):S41–S46PubMedGoogle Scholar
  29. 29.
    Gershanovich ML, Garin AM, Baltinia D, Kurvet A, Kangas L, Ellmen Iu (1997) Results of phase II clinical trial of Tamoxifen and Toremifen in two different doses in advanced breast cancer in postmenopausal women. Vopr Onkol 43:587–595PubMedGoogle Scholar
  30. 30.
    Holli K, Finnish Breast Cancer Group (2002) Tamoxifen versus toremifene in the adjuvant treatment of breast cancer. Eur J Cancer 38(Suppl 6):S37–S38CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  1. 1.Department of Hematology, The Second HospitalAnhui Medical UniversityHefeiChina

Personalised recommendations